Precision BioSciences FCF Margin

What does Precision BioSciences do? Precision BioSciences develops genome editing technologies, focusing on its ARCUS platform for precise DNA modification. The company creates nucleases to insert, remove, and alter DNA at specific genome locations, targeting therapeutic, agricultural, and biologics manufacturing applications. Its product pipeline includes four CAR T cell candidates: PBCAR0191, PBCAR20A, PBCAR269A, and PBCAR371A, designed for allogeneic CAR T immunotherapy. Precision BioSciences generates revenue through licensing ARCUS technology to partners in biopharmaceuticals and agriculture, with product candidates advancing toward clinical and commercial stages. The company targets biopharmaceutical firms seeking advanced genome editing tools for drug development and agricultural companies aiming for sustainable food solutions. ARCUS technology addresses limitations in current editing methods, enabling applications in human disease treatment and agricultural innovation. Precision BioSciences' focus on allogeneic CAR T therapies and in vivo gene correction positions it to serve clients requiring scalable, precise genetic solutions. Precision BioSciences' product candidates span therapeutic, agricultural, and biologics manufacturing segments, with CAR T cell therapies representing a key therapeutic focus. The company monetizes through technology licensing and development partnerships, leveraging its ARCUS platform to develop solutions that overcome existing genome editing constraints. Its pipeline includes both early-stage candidates and those progressing toward clinical validation for human therapeutic use. Precision BioSciences is one of the most popular companies on Eulerpool.